Read by QxMD icon Read


Monica Zolezzi, Oraib Abdallah, Nadir Kheir, Abdelsalam Gomaa Abdelsalam
BACKGROUND: Individuals who suffer from major cardiovascular events every year have one or more risk factors. Cardiovascular disease (CVD) risk assessment is an important strategy for the early identification of modifiable risk factors and their management. There is substantial evidence that shifting the focus from treatment to primary prevention reduces the burden of CVD. OBJECTIVES: To evaluate the preparedness of community pharmacists in Qatar for the provision of CVD risk assessment and management services; and to explore the pharmacists' views on the provision of these services...
April 28, 2018: Research in Social & Administrative Pharmacy: RSAP
Marilene Lopes Ângelo, Fernanda de Lima Moreira, André Luís Morais Ruela, Ana Laura Araújo Santos, Hérida Regina Nunes Salgado, Magali Benjamim de Araújo
Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. This drug is indicated for dyslipidemias treatment and can help to decrease the level of "bad cholesterol" and can consequently reduce the development of atherosclerosis and the risk of heart diseases. ROS was developed by Astra-Zeneca and it was approved in 2003 by the FDA in the United States. In 2015, under the trade name Crestor®, it was the fourth largest selling drug in the United States with sales above $5 billion...
March 13, 2018: Critical Reviews in Analytical Chemistry
Tung-Chen Yeh, Ching-Sen Shin, Hsin-Hung Chen, Chi-Cheng Lai, Gwo-Ching Sun, Ching-Jiunn Tseng, Pei-Wen Cheng
Resveratrol is a polyphenol with pleiotropic effects against oxidative damage that has been widely implicated in the lowering of hypertension risk. The purpose of this study was to determine whether improve NO release in the brain either through the activation of AMPK or reduced Rac1-induced ROS generation, thereby reducing BP in rats with fructose-induced hypertension. The rats were fed with 10% fructose or crestor (rosuvastatin; 1.5 mg/kg/day) and resveratrol (10 mg/kg/day) treatment for 1 week, the systolic blood pressure (SBP) of the rats were measured by tail-cuff method...
March 1, 2018: Journal of Applied Physiology
Hatice Yesim Karasulu, E Gundogdu, U O Turk, T Turgay, S Apaydın, I Yildırım Simsir, C Yılmaz, E Karasulu
The aim of this study was to develop new Rosuvastatin calcium (RCa) self emulsifying drug delivery system (SEDDS) and to evaluate the bioavailability and pharmacodynamic effect of RCa-SEDDS in Yorkshire pigs. Firstly, SEDDS was developed and prepared then RCa was incorporated into SEDDS which was evaluated regarding their characterization, stability properties, drug release profiles, permeation and cytotoxicity studies. Finally, in vivo performance of RCa-SEDDS (F1-RCa-SEDDS) was examined by pharmacokinetic and pharmacodynamics studies...
February 25, 2018: Current Drug Delivery
Lizhi Zhang, Zhong-Quan Liu
The carbon-carbon bond formation via autoxidation of organoboronic acid using 1 atm of O2 is achieved in a simple, clean, and green fashion. The approach allows a technically facile and environmentally benign access to structurally diverse heteroaromatics with medicinally privileged scaffolds. The strategy also displays its practicality and sustainability in the resynthesis of marketed drugs Crestor and pyrimethamine.
December 15, 2017: Organic Letters
Vyacheslav Zhdan, Galina Khaymenova, Lyudmila Shilkina, Daria Martynyuk, Marina Babanina, Tatyana Mamontova
INTRODUCTION: In complex treatment of chronic obstructive pulmonary disease (COPD) combined with ischemic heart disease (IHD) more and more attention is drawn to pleiotropic effect of statins. The aim of our researches became determining the effectivity of utilization of rosuvastatin (CRESTOR®, IPR PHARMACEUTICALS, Inc.) in complex treatment of COPD combined with IHD. MATERIALS AND METHODS: Basing on pulmonology department of Poltava regional clinical hospital, 30 patients with COPD combined with IHD have been examined (stable effort angina FC II) aged from 51 to 67 y...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
B Ya Bart, E E Luchinkina, I G Gordeev, G P Arutyunov, E O Taratukhin On Behalf Of The Workgroup Of Paritet Trial
The study is one of the priority points of the Russian Scientific Medical Society of Internal Medicine, initiated due to known high average level of LDL cholesterol in Russian population and necessity for its optimized control by better access to treatment. AIM: To conduct comparative analysis of efficacy and safety of the rosuvastatin compound akorta and original rosuvastatin crestor. MATERIAL AND METHODS: To randomized crossover study (PARITET) 60 patients were included with the diagnosis dyslipidemia...
June 2016: Kardiologiia
Rishi Puri, Steven E Nissen, Mingyuan Shao, Christie M Ballantyne, Phillip J Barter, M John Chapman, Raimund Erbel, Peter Libby, Joel S Raichlen, Kiyoko Uno, Yu Kataoka, Stephen J Nicholls
OBJECTIVES: The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. BACKGROUND: Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease. METHODS: SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months...
October 2014: JACC. Cardiovascular Imaging
Alexandra Sklan
No abstract text is available yet for this article.
May 2013: Pharmaceutical Patent Analyst
Luis M Moura, Sandra F Ramos, Steen D Kristensen, Fausto J Pinto, Isabel M Barros, Francisco Rocha-Gonçalves
BACKGROUND AND AIM OF THE STUDY: The study aims were to test the effect of rosuvastatin on the progression of left ventricular (LV) diastolic function in patients with aortic stenosis (AS), and to evaluate the use of beta-natriuretic-peptide (BNP) as a marker of diastolic dysfunction in this condition. METHODS: Sixty-one hypercholesterolemic, consecutive new referrals with moderate AS were administered rosuvastatin (Crestor) 20 mg/day for 18 months, while a further 60 subjects with normal cholesterol levels remained untreated...
July 2012: Journal of Heart Valve Disease
Hai-bo Yang, Xiao-yan Zhao, Yin-tao Zhao, Jin-ying Zhang, Ling Li
OBJECTIVE: To evaluate the effects of domestic rosuvastatin tablets on coronary plaque in the patients with mild-to-moderate coronary artery stenosis through virtual histology-intravascular ultrasound (VH-IVUS). METHODS: Eighty-three patients with mild-to-moderate coronary artery stenosis of acute coronary syndrome (ACS) were enrolled and randomized into test group (domestic rosuvastatin, 10 mg/day, n = 42) or control group (CRESTOR, 10 mg/day, n = 41). The serum lipid levels, diameter stenosis (DS) on quantitative coronary angiography (QCA), MLA (minimal lumen area), plaque burden and component of target lesion on VH-IVUS were evaluated at baseline and at 6-month follow-up...
June 12, 2012: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Fethi Trabelsi, Aleš Bartůnek, Raphaël Vlavonou, Lucie Navrátilová, Charlotte Dubé, Mario Tanguay, Tomáš Hauser
BACKGROUND: Rosuvastatin, a synthetic lipid-lowering agent acts selectively by competitive inhibition of 3-hydroxy- 3-methylglutaryl-coenzyme A. It is indicated as an adjunct to diet in patients with hypercholesterolemia and mixed dyslipidemia. OBJECTIVE: The purpose of this study was to demonstrate bioequivalence between a generic rosuvastatin 40 mg tablet (Zentiva, Prague, Czech Republic) and a reference product (Crestor, AstraZeneca, Luton, UK), under fasting conditions as required by the European Medicinal Agency...
October 2012: International Journal of Clinical Pharmacology and Therapeutics
Jackie Tan, Casper Francois Pretorius, Paul Vincent Flanagan, Antonio Pais
Rosuvastatin (Crestor, AstraZeneca) is a commonly used drug for managing hypercholesterolaemia. It is a very safe medication with mostly acceptable side effects. Rare but serious side effects are not well known. A 64-year-old woman presented with bloody diarrhoea after starting rosuvastatin for hypercholesterolaemia. Stool microscopy and culture ruled out infective causes. Abdominal CT scan revealed normal calibre celiac axis and superior mesenteric artery. Colonoscopic biopsy revealed ischaemic colitis as the final histological diagnosis...
2012: BMJ Case Reports
Samia Mora, Robert J Glynn, S Matthijs Boekholdt, Børge G Nordestgaard, John J P Kastelein, Paul M Ridker
OBJECTIVES: The goal of this study was to determine whether residual risk after high-dose statin therapy for primary prevention individuals with reduced levels of low-density lipoprotein cholesterol (LDL-C) is related to on-treatment apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), trigylcerides, or lipid ratios, and how they compare with on-treatment LDL-C. BACKGROUND: Guidelines focus on LDL-C as the primary target of therapy, yet residual risk for cardiovascular disease (CVD) among statin-treated individuals remains high and not fully explained...
April 24, 2012: Journal of the American College of Cardiology
Peter J Dunn
Green Chemistry or Sustainable Chemistry is defined by the Environmental Protection Agency as "the design of chemical products that reduce or eliminate the use of hazardous substances" In recent years there is a greater societal expectation that chemists and chemical engineers should produce greener and more sustainable chemical processes and it is likely that this trend will continue to grow over the next few decades. This tutorial review gives information on solvents and solvent selection, basic environmental metrics collection and three industrial case histories...
February 21, 2012: Chemical Society Reviews
Natalie J Carter
Rosuvastatin (Crestor®) is an HMG-CoA reductase inhibitor (statin) that has both lipid-lowering and anti-inflammatory effects. The drug has various indications in the US, including the primary prevention of cardiovascular disease (CVD) in patients with no clinical evidence of coronary heart disease who are at increased risk of CVD based on their age, a high-sensitivity C-reactive protein (hsCRP) level of ≥2 mg/L, and at least one other CVD risk factor. The efficacy of rosuvastatin in apparently healthy women (aged ≥60 years) or men (aged ≥50 years) with normal low-density lipoprotein cholesterol (LDL-C) levels and elevated hsCRP levels was demonstrated in the large, randomized, double-blind, multinational, JUPITER trial...
2010: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
Benjamin Yang
No abstract text is available yet for this article.
October 2003: Discovery Medicine
Paul M Ridker, Jean MacFadyen, Michael Cressman, Robert J Glynn
OBJECTIVES: We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease (CKD). BACKGROUND: Whether patents with moderate CKD (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2)) benefit from statin therapy is uncertain, particularly among those without hyperlipidemia or known cardiovascular disease. METHODS: Within the JUPITER (Justification for the Use of statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) primary prevention trial of rosuvastatin 20 mg compared with placebo among men and women free of cardiovascular disease who had low-density lipoprotein cholesterol (LDL-C) <130 mg/dl and high-sensitivity C-reactive protein (hsCRP) >or=2 mg/l, we performed a secondary analysis comparing cardiovascular and mortality outcomes among those with moderate CKD at study entry (n = 3,267) with those with baseline eGFR >or=60 ml/min/1...
March 23, 2010: Journal of the American College of Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"